Literature DB >> 6329113

Dopamine-sensitive adenylate-cyclase in rabbit superior mesenteric artery.

W L Collier, M De Rossi, F Amenta.   

Abstract

The effect of dopamine on 3'-5'-cyclic adenosine monophosphate (cAMP) generation in the rabbit superior mesenteric artery was studied in order to identify dopamine receptors. Dopamine added to homogenates of superior mesenteric artery increased the concentration of cAMP. The stimulation of cAMP levels elicited by dopamine was unaffected by alpha or beta-adrenergic receptor blocking agents but was remarkably reduced by the dopamine receptor blocking agents fluphenazine and haloperidol. The findings appear to indicate that the effects of dopamine on rabbit superior mesenteric artery are mediated through activation of the adenylate-cyclase cAMP system.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329113

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  4 in total

1.  Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.

Authors:  W D Kerns; E Arena; D G Morgan
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

2.  Dopamine inhibits prostaglandin F2 alpha-induced depolarization of rabbit jejunal arteries via activation of DA1-receptors.

Authors:  P Illes; W Nörenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-04       Impact factor: 3.000

3.  Peripheral vascular and neuronal effects of dopamine receptor agonists. A comparison with receptor binding studies in rat striatum.

Authors:  C Semeraro; R Ferrini; L Allievi; F Pocchiari; S Nicosia; C Casagrande
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-11       Impact factor: 3.000

4.  Potentiation of the effects of dopamine in the rabbit isolated splenic artery by 3-isobutyl-1-methylxanthine or forskolin.

Authors:  K L Clark; G M Drew; A Hilditch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-11       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.